These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32398657)

  • 1. Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment.
    Serpico AF; Visconti R; Grieco D
    Cell Death Dis; 2020 May; 11(5):361. PubMed ID: 32398657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.
    Harrison MR; Holen KD; Liu G
    Clin Adv Hematol Oncol; 2009 Jan; 7(1):54-64. PubMed ID: 19274042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.
    Henriques AC; Ribeiro D; Pedrosa J; Sarmento B; Silva PMA; Bousbaa H
    Cancer Lett; 2019 Jan; 440-441():64-81. PubMed ID: 30312726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
    Mosca L; Ilari A; Fazi F; Assaraf YG; Colotti G
    Drug Resist Updat; 2021 Jan; 54():100742. PubMed ID: 33429249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting microtubules for cancer chemotherapy.
    Zhou J; Giannakakou P
    Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.
    Harrison M; Swanton C
    Expert Opin Investig Drugs; 2008 Apr; 17(4):523-46. PubMed ID: 18363517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
    Alberti C
    Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marine Derived Anticancer Drugs Targeting Microtubule.
    De O; Chatterji BP
    Recent Pat Anticancer Drug Discov; 2017; 12(2):102-127. PubMed ID: 28067173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell.
    Hasanpourghadi M; Karthikeyan C; Pandurangan AK; Looi CY; Trivedi P; Kobayashi K; Tanaka K; Wong WF; Mustafa MR
    J Exp Clin Cancer Res; 2016 Mar; 35():58. PubMed ID: 27030360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubule active agents: beyond the taxane frontier.
    Morris PG; Fornier MN
    Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.
    Dowling M; Voong KR; Kim M; Keutmann MK; Harris E; Kao GD
    Cancer Biol Ther; 2005 Feb; 4(2):197-206. PubMed ID: 15753652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tubulin: an example of targeted chemotherapy.
    Seligmann J; Twelves C
    Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taxanes, microtubules and chemoresistant breast cancer.
    McGrogan BT; Gilmartin B; Carney DN; McCann A
    Biochim Biophys Acta; 2008 Apr; 1785(2):96-132. PubMed ID: 18068131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosomal instability, colorectal cancer and taxane resistance.
    Swanton C; Tomlinson I; Downward J
    Cell Cycle; 2006 Apr; 5(8):818-23. PubMed ID: 16628000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology and use of microtubule-targeting agents in cancer therapy.
    Zelnak AB
    Methods Mol Med; 2007; 137():209-34. PubMed ID: 18085232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotic checkpoint defects in human cancers and their implications to chemotherapy.
    Wang X; Cheung HW; Chun AC; Jin DY; Wong YC
    Front Biosci; 2008 Jan; 13():2103-14. PubMed ID: 17981695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.